688331
vs
S
Shanghai Composite
688331
Over the past 12 months, RemeGen Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +232% compared to the Shanghai Composite's +25% growth.
Stocks Performance
688331 vs Shanghai Composite
Performance Gap
688331 vs Shanghai Composite
Performance By Year
688331 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
RemeGen Co Ltd
Glance View
In the bustling landscape of China's biopharmaceutical industry, RemeGen Co Ltd stands as a beacon of innovation and determination. Founded in 2008 and headquartered in Yantai, the company swiftly positioned itself as a frontrunner in the development of novel biologic therapies. With its operation straddling cutting-edge research and development facilities and state-of-the-art production capabilities, RemeGen focuses on addressing unmet medical needs in the realms of oncology and autoimmune diseases. Their work fundamentally consists of harnessing the power of human biology to create targeted therapies, a task which involves a rigorous process of discovery, clinical trials, and regulatory approvals before a drug can be brought to market. The company's business model relies significantly on its ability to advance promising candidates through the clinical pipeline and secure partnerships with international pharmaceutical giants. This not only helps in sharing the financial risks associated with drug development but also accelerates market access for its therapies. Revenue streams for RemeGen primarily come from sales of its proprietary drugs, licensing agreements, and milestone payments tied to research achievements or commercial successes. By aligning with global standards for drug development, RemeGen not only nurtures its own product portfolio but also attracts strategic collaborations, making it a formidable player in the global life sciences ecosystem.
